Pasadena Private Wealth’s Citius Pharmaceuticals CTXR Stock Holding History

Pasadena Private Wealth’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-439	Closed	-$7.5K	–	155
2023 Q3	$7.5K	Hold	439	–	–	﹤0.01%	97
2023 Q2	$13.2K	Hold	439	–	–	﹤0.01%	107
2023 Q1	$12.8K	Hold	439	–	–	﹤0.01%	100
2022 Q4	$8.66K	Hold	439	–	–	﹤0.01%	99
2022 Q3	$13K	Buy	+439	New	+$12.1K	﹤0.01%	92

Other funds holding CTXR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pasadena Private Wealth's CTXR Position: Q4 2023 in Review

Pasadena Private Wealth sold out of Citius Pharmaceuticals (CTXR) in Q4 2023, closing a stake of 439 shares — an estimated $7.5K sold.

Pasadena Private Wealth first reported a position in CTXR in Q3 2022 and held it in 5 quarters. The position peaked at $13.2K in Q2 2023. 74 funds tracked by Wall St. Rank hold CTXR as of Q4 2023.

Pasadena Private Wealth reported no remaining Citius Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Pasadena Private Wealth sold 439 Citius Pharmaceuticals shares in Q4 2023, an estimated $7.5K.
Pasadena Private Wealth first reported a position in Citius Pharmaceuticals in Q3 2022 and held it in 5 quarters.
Pasadena Private Wealth's Citius Pharmaceuticals position peaked at $13.2K in Q2 2023.
74 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2023.

Based on Pasadena Private Wealth's 13F filing for Q4 2023, filed 10 Jan 2024.